Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 40Tumor-Agnostic 28Breast 19Thoracic 5Gynecologic 4Genitourinary 4Head & Neck 3Sarcoma 2Lymphoid 2Dermatologic 2CNS 2Plasma cell 1Other 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 11Zollinger-Ellison Syndrome 2Vipoma 2Somatostatinoma 2Pheochromocytoma 2Carcinoma, Neuroendocrine 2Carcinoma, Medullary 2Carcinoid Tumor 2Pancreatic Neoplasms 1Non functioning pancreatic endocrine tumor 1Neoplasms 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Insulinoma 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastro-entero-pancreatic Neuroendocrine Tumors 1Gastrinoma 1Carcinoma, Merkel Cell 1Adrenal Cortex Neoplasms 1

Interventions

Everolimus 5Sunitinib 4lutetium Lu 177 dotatate 2PM 01183 2Octreotide 2Doxorubicin 2trifluridine tipiracil drug combination 1telotristat ethyl 1repotrectinib 1pralsetinib 1pegfilgrastim 1pasireotide 1motesanib diphosphate 1epothilone B 1dactolisib 1copper dotatate CU-64 1batifiban 1avelumab 1alectinib 1Temozolomide 1TKM-080301 1Surveys and Questionnaires 1SNX-5422 1Referral and Consultation 1Radiomics 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Molecular Diagnostic Techniques 1Lutetium-177 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Capecitabine × NET × Clear all
NCT07012330 2025-06-10

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

Erasmus Medical Center

Phase 2 Terminated
111 enrolled
EndocrineNET

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡